RPG Life SciencesNSE:RPGLIFE +0.92%92 Altman Z-Score is 15.87 as of Jul. 04, 2026, which is 88% above its 10-year median of 8.43. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 92/100 and a GF Value™ of ₹2,353.32 (Fairly Valued). The stock has 5 warning signs investors should review. Among 951 Drug Manufacturers companies, RPG Life Sciences ranks better than 91.69% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 15.87 is strong.
RPG Life Sciences has a Altman Z-Score of 15.87, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for RPG Life Sciences's Altman Z-Score or its related term are showing as below:
NSE:RPGLIFE'
s Altman Z-Score Range Over the Past 10 Years
Min: 4.55 Med: 8.43 Max: 21.59
Current: 15.87
During the past 13 years, RPG Life Sciences's highest Altman Z-Score was 21.59. The lowest was 4.55. And the median was 8.43.
RPG Life Sciences (NSE:RPGLIFE) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
RPG Life Sciences Altman Z-Score Related Terms
RPG Life Sciences Altman Z-Score Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RPGLIFE vs ZTS, UTHR: Altman Z-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
RPG Life Sciences's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.5029
+
1.4
*
0.6922
+
3.3
*
0.1955
+
0.6
*
21.2741
+
1.0
*
0.892
=
15.87
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
RPG Life Sciences (NSE:RPGLIFE) has a Altman Z-Score of 15.87 as of Jul. 04, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on RPG Life Sciences and its competitors. This is 88% above median its historical median of 8.43. Over the past decade, RPG Life Sciences' Altman Z-Score has ranged from 4.55 to 21.59. According to the industry distribution chart, RPG Life Sciences ranks #79 out of 951 companies in the Drug Manufacturers industry, placing it in the top 8.3%.
Is RPG Life Sciences' Altman Z-Score too high?
RPG Life Sciences' current Altman Z-Score of 15.87 is 88% above median its 10-year median of 8.43. Over the past 10 years, this metric has ranged from a low of 4.55 to a high of 21.59. The Drug Manufacturers industry median Altman Z-Score is 3.23. RPG Life Sciences' value of 15.87 is 391.3% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #79 out of 951 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, RPG Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #79 out of 951 companies for Altman Z-Score. This places RPG Life Sciences in the top 8% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.23. RPG Life Sciences' value of 15.87 is 391.3% above this benchmark. Historically, RPG Life Sciences' own Altman Z-Score has ranged from 4.55 to 21.59 over the past decade. While the company's 10-year median is 8.43 vs. the industry median of 3.23, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.23, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current Altman Z-Score of 15.87 is 391.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current Altman Z-Score is 15.87, which is 88% above median its own 10-year median of 8.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,353.32, compared to a current price of ₹2,415.80 — trading 2.7% above its estimated fair value. The current Altman Z-Score is 15.87, which is 88% above median its 10-year median of 8.43 and 391.3% above the Drug Manufacturers industry median of 3.23. RPG Life Sciences' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current Altman Z-Score is 15.87 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,415.80 is trading 2.7% above its estimated GF Value™ of ₹2,353.32.
GuruFocus considers RPG Life Sciences to be Fairly Valued.
Key valuation signals for NSE:RPGLIFE:
Altman Z-Score: 15.87 (88% above median its 10-year median of 8.43)
GF Value™: ₹2,353.32 vs. price of ₹2,415.80 (2.7% above fair value)
Industry Position: 391.3% above the Drug Manufacturers median (#79 of 951)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
92GF Score
Get the complete analysis for NSE:RPGLIFE
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
